SEC Contract Filing

Filing Date: 2024-05-23

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea020671501ex10-1_abvcbio.htm
<DESCRIPTION>LETTER AGREEMENT
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 22, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Inducement
Offer to Exercise Existing Warrants to Purchase Common Stock</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Reference
is made to that certain (i) Common Stock Purchase Warrant issued by ABVC Biopharma, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;)
to Lind Global Fund II LP (the &ldquo;<U>Holder</U>&rdquo;), on February 23, 2023, to initially purchase 5,291,667 shares (529,167 shares
after the </FONT>after the July 2023 <FONT STYLE="background-color: white">1-for-10 reverse stock&nbsp;</FONT>split) <FONT STYLE="font-size: 10pt">of
the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;) (the &ldquo;<U>First Warrant</U>&rdquo;),
(ii) Common Stock Purchase Warrant issued by the Company to the Holder, on November 17, 2023, to initially purchase 1,000,000 shares of
Common Stock (the &ldquo;<U>Second Warrant</U>&rdquo;), and (iii) Common Stock Purchase Warrant issued by the Company to the Holder, on
January 17, 2024, to initially purchase 1,000,000 shares of Common Stock (the &ldquo;<U>Third Warrant</U>&rdquo;, and together with the
First Warrant and the Second Warrant, the &ldquo;<U>Existing Warrants</U>&rdquo;). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are pleased to offer to
the Holder the opportunity to receive (i) a new warrant to purchase shares of Common Stock, and (ii) a modification in the current exercise
price (the &ldquo;<U>Exercise Price</U>&rdquo;) of the Existing Warrants in consideration for you exercising for cash a portion of the
Existing Warrants into 1,000,000 shares of Common Stock (the &ldquo;<U>Warrant Purchase Amount</U>&rdquo;). The resale of the Common Stock
underlying the Existing Warrants (the &ldquo;<U>Warrant Shares</U>&rdquo;) has been registered for resale pursuant to the registration
statement on the Company&rsquo;s Registration Statement (the &ldquo;<U>Registration Statement</U>&rdquo;) on Form S-1 (File number 333-276500
under the Securities Act of 1933, as amended (&ldquo;<U>Securities Act</U>&rdquo;)). The Registration Statement is currently effective
and, upon your exercise of your Existing Warrants pursuant to this letter agreement, will be effective for the resale of the Warrant Shares.
Capitalized terms not otherwise defined herein shall have the meanings set forth in the New Warrants (as defined herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company desires to modify
the Exercise Price of the Existing Warrants to $0.75 per share&nbsp;(the &ldquo;<U>New Exercise Price</U>&rdquo;). In consideration for
you exercising the Existing Warrants as provided herein (the &ldquo;<U>Warrant Exercise</U>&rdquo;), the Company hereby offers to issue
to you or your designees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) a new unregistered warrant
to subscribe for Common Stock (&ldquo;<U>New Warrant</U>&rdquo;) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended
(&ldquo;<U>Securities Act</U>&rdquo;), to subscribe for up to a number of Common Stock (the &ldquo;<U>New Warrant Shares</U>&rdquo;) equal
to 100% of the number of Warrant Shares issued pursuant to each Warrant Exercise hereunder, which New Warrant shall be substantially in
the forms as set forth in&nbsp;<U>Exhibit A</U> &nbsp;hereto, exercisable at any time on or after the date of its issuance and until the
five year anniversary thereof, for $1.00 per New Warrant Share.&nbsp; &nbsp;&nbsp;For avoidance of doubt, the amount of New Warrant Shares
shall be limited to those Warrant Shares issued pursuant to the exercise made under paragraph (c) herein and not any other future exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The New Warrants certificate(s)
will be delivered within five (5) Trading Days following the date hereof, and such New Warrants, together with any underlying Common Stock
issued upon exercise of the New Warrants, will, unless and until registered, contain customary restrictive legends and othe